1. Scrip

Optum Rx Reveals Humira Biosimilar Plan To ‘Support Advancement" Of The Market

 
• By Jessica Merrill

United Health's pharmacy benefit manager outlined plans for early inclusion of up to three biosimilar versions of adalimumab on its formularies in 2023, at parity to the brand.

stone scale
Optum Rx plans to offer Humira brand and biosimilars at parity • Source: Shutterstock

United Health Group, Inc.'s inhouse pharmacy benefit manager (PBM) Optum Rx plans to include up to three biosimilar versions of AbbVie Inc.'s Humira (adalimumab) on its formularies in 2023, beginning with the first one that becomes available. The PBM is one of the first big players to outline its strategy for incorporating biosimilar versions of Humira on formularies, which will play an important role in how quickly the brand market share erodes and how quickly biosimilars gain traction.

"The availability of Humira biosimilars is one of the biggest opportunities in years to lower costs and increase accessibility for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

More from Scrip

Europe’s Drugmakers Lament EU Pharma Package

 
• By Kevin Grogan

EFPIA says reforms make the continent less attractive for innovative firms.

Lyra Eyes US Filing For LYR-210 After Surprise ENLIGHTEN 2 Win

 
• By Sushmita Panda

In a turn of fortunes, Lyra Therapeutics has reported positive Phase III results for LYR-210 in chronic rhinosinusitis, boosting hopes for US approval. The company plans to submit an NDA and pursue further trials, but its cash position is precarious.

Deal Watch: Lilly Licenses Camurus’s Delivery Technology For Long-Acting Incretins

 
• By Joseph Haas

Plus deals involving Roche/Vividion, Alto/Chase, Biogen/City Therapeutics, Sanofi/Nurix and Naya/Invo.